skip to main content

Roderick Dashwood

Roderick H. Dashwood,PhD, FRSB

Professor and Center Director, Center for Epigenetics and Disease Prevention

John S. Dunn Chair in Disease Prevention

Assistant: Ceciley Brinn, 713-677-7524


cancer, preventable disease, genetics, epigenetic mechanisms, dietary factors as anti-cancer agents
Roderick H. Dashwood

About Roderick H. Dashwood

Dr. Dashwood completed schooling through bachelors, masters, and PhD degrees in England, and then joined Oregon State University in 1986 as a postdoctoral research associate. This began a research career focused on the molecular mechanisms of cancer prevention. Academic positions at the University of Hawaii were followed by sabbaticals at the National Cancer Center in Tokyo.

Dr. Dashwood returned to Oregon State University in 1997 as director of the Cancer Chemoprotection Program and was appointed Helen P. Rumbel Professor for Cancer Prevention. His research initially focused on the genetic aspects of colorectal cancer, including key contributions in the area of Wnt signaling, but moved into the realm of epigenetics with the discovery of the histone deacetylase (HDAC) inhibitory activity of sulforaphane.

In 2013, Dr. Dashwood relocated to the Texas Medical Center and became director of the Center for Epigenetics & Disease Prevention at Texas A&M College of Medicine in Houston. He has affiliated positions (i) in the Department of Nutrition & Food Science/AgriLife Research at Texas A&M University, (ii) in the Department of Molecular & Cellular Medicine at Texas A&M College of Medicine, and (iii) in the Department of Clinical Cancer Prevention at The University of Texas MD Anderson Cancer Center. Dr. Dashwood's current research encompasses histone and non-histone modifications, DNA methylation, and non-coding RNAs, in the continuum from computational modeling in silico, to cell-based assays and preclinical models, and into human trials. His has published more than 200 peer-reviewed articles and has service on NIH study sections and journal editorial boards and NCI-funded grants and contracts. In 2016, he was appointed to the External Steering Panel of the National Cancer Institute (NCI) PREVENT Program, and in 2017, he was elected Fellow of the Royal Society of Biology.